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Abstract
Cannabinoids exert complex actions on neurotransmitter systems involved in cognition, locomotion, appetite, but no information was
available so far on the interactions between the endocannabinoid system and histaminergic neurons that command several, similar
behavioural states and memory. In this study, we investigated the effect of cannabimimetic compounds on histamine release using
the microdialysis technique in the brain of freely moving rats. We found that systemic administration of the cannabinoid receptors 1
(CB1-r) agonist arachidonyl-2¢chloroethylamide ⁄N-(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA; 3 mg ⁄ kg) increased
histamine release from the posterior hypothalamus, where the histaminergic tuberomamillary nuclei (TMN) are located. Local
infusions of ACEA (150 nm) or R(+)-methanandamide (mAEA; 1 lm), another CB1-r agonist, in the TMN augmented histamine
release from the TMN, as well as from two histaminergic projection areas, the nucleus basalis magnocellularis and the dorsal
striatum. When the endocannabinoid uptake inhibitor AM404 was infused into the TMN, however, increased histamine release was
observed only in the TMN. The cannabinoid-induced effects on histamine release were blocked by co-administrations with the CB1-r
antagonist AM251. Using double-immunofluorescence labelling and confocal laser-scanning microscopy, CB1-r immunostaining was
found in the hypothalamus, but was not localized onto histaminergic cells. The modulatory effect of cannabimimetic compounds on
histamine release apparently did not involve inhibition of c-aminobutyric acid (GABA)ergic neurotransmission, which provides the
main inhibitory input to the histaminergic neurons in the hypothalamus, as local infusions of ACEA did not modify GABA release from
the TMN. These profound effects of cannabinoids on histaminergic neurotransmission may partially underlie some of the behavioural
changes observed following exposure to cannabinoid-based drugs.
Introduction
The endocannabinoid system plays an important neuromodulatory role
in brain physiology, fine-tuning information flow in neuronal networks
associated with cognitive processing, emotion, pain perception and
appetite (Di Marzo & Matias, 2005). Endocannabinoids are generally
made on demand, bind with high affinity to cannabinoid receptors 1
(CB1-r), and are rapidly eliminated by a carrier-mediated transport
followed by intracellular enzymatic metabolism (Piomelli, 2003). For
example, endocannabinoids release in the hypothalamus regulates
appetitive behaviour (Kirkham et al., 2002), whereas in the basal
ganglia it counteracts the stimulation of movement induced by
dopamine agonists (Beltramo et al., 2000). Furthermore, recent studies
indicated that endocannabinoids content rises in restricted brain areas
engaged in the processing of emotional information (Marsicano et al.,
2002). CB1-r mediate not only the physiological effects of endocann-
abinoids, but also the psychotropic effects of D9-tetrahydrocannabinol
(D9-THC). Exogenous cannabinoids induce a broad array of beha-
vioural responses that include catalepsy, reduced movement and
hypothermia (Pertwee, 1997). Furthermore, behaviours ranging from
relaxation and sedation to anxiety and panic attacks have been
observed (Zuardi et al., 1982).
Histaminergic neurons are located in the hypothalamic tuberomam-
illary nuclei (TMN) and send projections to various brain regions,
hence regulating the sleep–wake cycle, energy and endocrine meta-
bolism, and learning (Haas & Panula, 2003). Histaminergic axonal
arborizations in the hypothalamus are involved in the release of
several hypothalamic hormones (Knigge et al., 1999), and food
consumption is accompanied by increased histamine release in the
hypothalamus (Itoh et al., 1991). Histamine can enhance cortical
activity by stimulating the cholinergic neurons of the nucleus basalis
magnocellularis (NBM; Dringenberg & Kuo, 2003), as activation of
histamine H1 receptors in the NBM increases acetylcholine (ACh)
release from the cortex (Cecchi et al., 2001). Histaminergic afferents
also innervate the striatum, a brain region that contains a high density
of H2 (Traiffort et al., 1992) and H3 (Pollard et al., 1993) receptors
and is important for proper motor function and in mediating
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stimulus–response habit formation (Gerdeman et al., 2003). In the
striatum, histamine induces hypokinetic effects that are accompanied
by altered dopaminergic transmission (Chiavegatto et al., 1998).
We therefore explored the possibility that the cannabinoid system
exerts some of its behavioural effects by modulating, or acting in
concert with, the activity of histaminergic neurons. Using the
microdialysis technique in freely moving rats, selective, directly
acting cannabinoid CB1-r agonists or an indirectly acting inhibitor of
endocannabinoid uptake were given locally into the TMN, and their
effect on histamine release was monitored in the TMN itself, in the
NBM and striatum. We show that cannabinoids, at the low concen-
trations used in this study, have an excitatory effect on the
histaminergic system.
CB1-r activation modulates neuronal activity by hyperpolarizing the
cell and ⁄ or inhibiting the release of neurotransmitters such as
c-aminobutyric acid (GABA). As histaminergic neurons receive
prominent innervations from sleep active GABAergic neurons of the
ventrolateral preoptic nucleus (Sherin et al., 1998), we also measured
the effect of cannabinoids on GABA release from the hypothalamus.
Finally, we used immunohistochemical techniques to establish whe-
ther there is a similar distribution of CB1-r and histaminergic fibres in
the hypothalamus.
Materials and Methods
Male, 8–9-week-old Sprague–Dawley rats (250–280 g ⁄wt, Harlan,
Italy) were housed in groups of three in a temperature-controlled room
(20–24 C), on a 12 h light : dark cycle, and were allowed free access
to food and water. All the experiments were done in strict compliance
with the EEC recommendations for the care and use of laboratory
animals (86 ⁄ 609 ⁄CEE), and were approved by the Animal Care
Committee of the ‘Dipartimento di Farmacologia Preclinica e Clinica’
of the ‘Universita´ di Firenze’.
Surgical procedures
Rats, anaesthetized with chloral hydrate (400 mg ⁄ kg i.p.) and
positioned in a stereotaxic frame (Stellar, Stoelting, Wood Dale, IL,
USA), were implanted with one or two guide cannulae (Metalant,
Sweden) according to the following coordinates from bregma (Paxinos
& Watson, 1998): TMN, AP ¼ )4.3, L ¼ )1.1, DV ¼ )7.2; NBM,
AP ¼ )0.8; L ¼ )2.8; DV ¼ )6.5; dorsal striatum, AP ¼ 0,
L ¼ )4, DV ¼ )4. A surgical screw served as an anchor and the
cannulae were fixed to the skull with acrylic dental cement.
In vivo microdialysis measurements of histamine
The microdialysis experiments were performed 24 h after surgery,
during which rats, housed one per cage, recovered from surgery. The
stylet was removed from the guide cannulae and the microdialysis
probes (molecular weight cut-off, 6000 Da; Metalant) were inserted;
the dialysing membrane protruded 2 mm from the tip of the cannula.
Both probes were perfused with Ringer’s solution (in mm: NaCl, 147;
CaCl2, 1.2; KCl, 4.0; pH 7.0) at a flow rate of 2 lL ⁄min using a
microperfusion pump (Carnegie Medicine, Sweden; Mod CMA ⁄ 100).
Histamine release stabilized 2 h after insertion of the microdialysis
probes, and fractions were collected at 15-min intervals. Spontaneous
release was defined as the average value of the four 15-min fractions
collected during 1 h of perfusion with Ringer’s solution prior to drug
treatment. All subsequent fractions were expressed as a percentage of
this value. To prevent degradation of histamine, 1.5 lL of 5 mm HCl
was added to each sample. The dialysates were kept at )80 C until
analysis. Drugs were supplied in 100% EtOH that was diluted
1 : 90 000 in the final solution. For arachidonyl-2¢chloroethyla-
mide ⁄N-(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA)
i.p. administration, EtOH concentration was 60%. Control injections
with saline contained 60% EtOH.
Histology
The placement of microdialysis membranes was verified post mortem.
Rats were overdosed with chloral hydrate, the brains removed and
stored in 10% formalin for 10 days. Forty-micrometre sections were
then sliced on a cryostat, mounted on gelatin-coated slides and then
stained with Cresyl violet for light microscopic observation. Data from
rats in which the membranes were not correctly positioned were
discarded. Typical probe placements are shown in Fig. 1.
Determination of histamine concentration by high-performance
liquid chromatography (HPLC)-fluorimetry
Histamine contents in the dialysates were determined by HPLC-
fluorimetry using a modified version of the protocol by Yamatodani
et al. (1985). Briefly, the column (Hypersil ODS, 3 lm,
2.1 · 100 mm; Thermo Electron Corporation, Bellefonte, PA, USA)
was eluted with 0.25 m potassium dihydrogen phosphate containing
5% octanesulphonic acid (Sigma) at a flow rate of 0.4 mL ⁄min. The
eluate from the column was mixed first with 0.1% o-phthalaldehyde
(OPA) solution at a flow rate of 0.1 mL ⁄min and then to a solution
containing 4 m sodium hydroxide and 0.2 m boric acid (flow rate
0.137 mL ⁄min) to adjust the reaction mixture to pH 12.5. The
reaction took place at 45 C. Then 17% orthophosphoric acid was
added to the solution (flow rate 0.137 mL ⁄min) to reach a final
reaction mixture at pH 3. The fluorescent intensity was measured with
a spectrofluorometer (Agilent series 1100, Waldbronn, Germany) at
450 nm with excitation at 360 nm.
Assay of GABA in the dialysate
GABA analysis was carried out by HPLC with fluorimetric detection
after OPA derivatization as previously described (Bianchi et al., 1999).
The OPA-derivatives were separated on a 5 lm reverse-phase
Nucleosil C18 column (200 · 4.6 mm i.d., Machery-Nagel, Duren,
Germany) at room temperature, using as mobile phase methanol and
potassium acetate (0.1 m, pH adjusted to 5.52 with glacial acetic acid),
eluting at 1 mL ⁄min flow rate in a three-step linear gradient, from
25% to 90% methanol.
Immunohistochemistry
Young adult male Sprague–Dawley rats were deeply anaesthetized
with chloral hydrate and perfused transcardially with 50 mL physio-
logical saline followed by 4% paraformaldehyde in 0.1 m phosphate
buffer (PB), pH 7.4. Brains were then postfixed in 4% paraformal-
dehyde in PB for 2 h at 4 C. Brains were cryoprotected in 30%
sucrose in PB, and 40-lm-thick sections were cut on a cryostat
microtome and collected in PB. All immunostaining procedures were
performed on free-floating sections. For double-labelling of CB1-r and
histaminergic cells, sections were preincubated with 5% normal
donkey serum (NDS, Jackson Immunoresearch, West Grove, PA,
USA), 2.5% bovine serum albumin (BSA, Sigma) and 0.5% Triton
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X-100 in PB for 1 h at room temperature. Sections were then
incubated in a cocktail of goat anti-CB1-r antibodies (1 : 1000,
directed against the C-terminal; Ha´jos et al., 2000) and rabbit anti-
histidine decarboxylase (HDC, 1 : 1000; Acris, Bad Nauheim,
Germany) primary antibodies in PB containing 0.5% Triton X-100,
0.1% BSA and 1% NDS for 48 h at 4 C. After thorough rinsing in
PB, sections were incubated in Cy3-conjugated donkey anti-goat IgG
(1 : 200; Jackson Immunoresearch) for 2 h at room temperature. After
extensive rinses in PB, sections were incubated in Alexa Fluor 488-
labelled, donkey anti-rabbit IgG (Molecular Probes, Eugene, OR,
USA) diluted 1 : 200 in PB containing 2% BSA for 1 h at room
temperature. Sections were then mounted on glass slides and
coverslipped with 70% glycerol in PB. Preadsorption of the CB1-r
antibodies with glutathione-S-transferase-conjugated fusion protein
(1 lg ⁄mL), or elimination of the primary antibodies resulted in no
immunostaining. Observations were performed with a Bio-Rad MCR
1024 ES confocal laser-scanning microscope (Bio-Rad, Hercules, CA,
USA) equipped with a Krypton ⁄Argon laser source 15 mW for
fluorescence measurements. Series of optical sections (512 · 512 pix-
els) were taken through the depth of the specimens with a thickness of
1 lm at the intervals of 0.8 lm by using a Nikon Planapo · 60 (· 40)
1.4 oil immersion objective. Twenty optical sections for each sample
were examined and projected as a single composite image by
superimposition. To avoid bleed-through, dual channel scanning of
signals from Cy3 and Alexa Fluor 488 were recorded separately and
saved in two different files.
Drugs
ACEA, R(+)-methanandamide (mAEA), AM251 and AM404 were
purchased from Tocris Cookson (Avonmouth, UK). For systemic
administrations, ACEA was injected i.p. diluted in physiological
saline. Bicuculline methiodide was purchased from Sigma.
Fig. 1. Schematic diagram and photomicrographs showing the position of the microdialysis probes. Rats were implanted with one probe in the tuberomamillary
nuclei (TMN) to deliver drugs locally and measure neurotransmitter release, and another probe in either the nucleus basalis magnocellularis (NBM) (A) or the dorsal
striatum (B) to measure histamine release. A single probe was implanted in the TMN, when measuring c-aminobutyric acid (GABA), or when drugs were
administered i.p. (C). (D–F) Representative histological structures showing the actual site of probe placement.
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Statistics
All values are expressed as means ± SEM, and the number of rats
used in each experiment is also indicated. The presence of significant
treatment effects was first determined by a one-way anova followed
by Fisher’s PSLD test or with two-way anova. For all statistical tests,
P < 0.05 was considered significant. For clarity purposes we reported
in figures and figure legends only the significant differences vs. the last
sample before drug treatment. However, differences were significant
vs. all baseline samples. Statistical analysis was performed using
StatView (Abacus Concepts, Berkley, CA, USA).
Results
After 120 min of equilibration following the insertion of the dialysing
membranes, histamine was released spontaneously at a stable rate of
0.19 ± 0.03 pmol ⁄ 15 min from the TMN (n ¼ 70), 0.25 ± 0.03
pmol ⁄ 15 min from the NBM (n ¼ 33), and 0.09 ± 0.04 pmol ⁄
15 min from the dorsal striatum (n ¼ 7).
Systemic administration of a CB1 receptor agonist increased
histamine release from the TMN
The effect of a single intraperitoneal injection of the selective and
potent CB1-r agonist ACEA (Hillard et al., 1999) on histamine release
from the TMN is shown in Fig. 2. ACEA (3 mg ⁄ kg, i.p.; n ¼ 8)
significantly increased histamine efflux from the TMN 60 min after
the injection compared with vehicle treatment (n ¼ 4), up to a peak
value of 84 ± 30%. Histamine release slowly returned to basal levels
over the next 60 min.
Perfusion of CB1-r agonists into the TMN increased histamine
release from the TMN and NBM
Using a double-probe microdialysis protocol, ACEA was infused
locally in the TMN and histamine release was monitored from the
TMN and NBM. As shown in Fig. 3A, 60 min perfusion with 150 nm
ACEA induced a significant increase in histamine release from both
the TMN and the NBM. In the TMN a significant increase of
histamine release was present during the first 15-min fraction
of ACEA administration and reached a maximum level of 122 ± 7%
of spontaneous release (n ¼ 5). Histamine release returned gradually
to baseline values during ACEA wash out. Histamine release also
increased in the NBM when ACEA was infused into the TMN and it
reached a maximal level of approximately 400 ± 146% within the first
30 min of TMN perfusion. A similar, significant increase of histamine
release from both the TMN and NBM was also observed following
perfusion of the TMN for 60 min with 1 lm mAEA, a synthetic
analogue of the endocannabinoid anandamide resistant to degradation
(Abadji et al., 1994). In the TMN, the maximal effect was of similar
magnitude and time course to that observed with ACEA (the maximal
increase was 155 ± 78%; n ¼ 4; Fig. 3B). In the NBM, histamine
release increased significantly during the first 15-min fraction of TMN
perfusion with 1 lm mAEA, and the maximal effect was 98 ± 34% of
spontaneous, baseline release (n ¼ 4). Histamine output tended to
remain elevated for the duration of mAEA application to the TMN and
then returned quickly to baseline values in both the TMN and NBM
after mAEA perfusion ended.
Perfusion of CB1-r agonists into the TMN increased histamine
release from the dorsal striatum
Perfusion of the TMN for 60 min with either 150 nm ACEA (n ¼ 3;
Fig. 4A) or 1 lm mAEA (n ¼ 4; Fig. 4B) increased histamine
release in the TMN as well as the dorsal striatum. Histamine levels
returned to basal values during wash out of the compounds. ACEA
increased histamine release significantly, up to 91 ± 35% in the
TMN and up to 173 ± 65% of basal levels in the striatum during the
third, 15-min period of pharmacological stimulation. Similarly, 1 lm
mAEA infused in the TMN augmented histamine release locally to a
maximum of 88 ± 40% of basal values (Fig. 4B), whereas histamine
release from the dorsal striatum was augmented up to a maximum of
145 ± 63%.
Effect of TMN perfusion with AM404 or AM251 on histamine
release
As endocannabinoid action is presumably terminated by cellular
uptake via an endocannabinoid membrane transporter (Piomelli,
2003) and by amidohydrolysis (Deutsch & Chin, 1993; McKinney &
Cravatt, 2005), we tested whether endocannabinoids reached a
sufficient concentration to activate their receptors and modulate the
activity of histaminergic cells by blocking their uptake and
metabolism in the hypothalamus. Presumably, both mechanisms are
blocked by AM404 (Jarrahian et al., 2000). When AM404 (100 lm)
was added to the TMN-perfusing medium for 60 min, histamine
release in the TMN increased by a maximum of 165 ± 58%, but was
not significantly changed in the NBM (Fig. 5A; n ¼ 5). In the TMN,
a significant increase was achieved during the fourth, 15-min period
of perfusion in the presence of AM404 and persisted for approxi-
mately 45 min during wash out, after which basal histamine levels
were attained. Perfusion of the TMN for 60 min with the selective
CB1-r antagonist AM251 at a concentration of either 200 nm
(Fig. 5B; n ¼ 5) or 10 lm (not shown; n ¼ 3) did not change
spontaneous histamine release significantly from the TMN (Fig. 5B,
lower panel) and consequently from the NBM (Fig. 5B, upper
panel).
Fig. 2. Time course of histamine release from the tuberomamillary nuclei
(TMN) of freely moving rats after systemic administration of the CB1-r agonist,
arachidonyl-2¢chloroethylamide ⁄N-(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatet-
raenamide (ACEA). Histamine release was measured in fractions collected
every 15 min. ACEA was administered i.p., whereas control animals received
1 mL ⁄ kg of vehicle containing 60% ethanol. Control values of spontaneous
histamine release were calculated for each experiment by averaging the mean of
four initially collected 15 min samples. Histamine release was expressed as a
percentage of spontaneous release. The arrow indicates the time of i.p.
injections. Represented are means ± SEM of eight–four experiments.
*P < 0.05 vs. last sample before drug treatment (anova and Fischer’s test).
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Perfusion of TMN with the CB1-r antagonist blocked the effect of
mAEA on histamine release
To confirm that the excitatory effects of cannabimimetic compounds
were mediated through activation of CB1-r, the CB1-r antagonist
AM251 was co-administered together with the CB1-r agonist mAEA
in the TMN, and histamine release was measured both in the TMN and
NBM. After collection of four, 15-min baseline samples, 200 nm
AM251 was added to the perfusing medium for 15 min, and then it
was administered in combination with the CB1-r agonist for an
Fig. 3. Influence of cannabinoid administration into the tuberomamillary nuclei (TMN) on histamine release from the TMN and nucleus basalis magnocellularis
(NBM) of freely moving rats. Histamine was measured in 15-min fractions and expressed as a percentage of spontaneous release, calculated as described in Fig. 2.
(A) Arachidonyl-2¢chloroethylamide ⁄ N-(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA) was infused into the TMN and histamine release was measured
from the TMN (lower panel) and the NBM (upper panel). (B) R(+)-Methanandamide (mAEA) was infused in the TMN and histamine release was measured in the
TMN (lower panel) and NBM (upper panel). Bars indicate the period of drug application. Shown are means ± SEM of four–five experiments. **P < 0.01; *P < 0.05
vs. last sample before drug treatment (anova and Fisher’s test).
Fig. 4. Effect of cannabinoid infusion into the tuberomamillary nuclei (TMN) on spontaneous histamine release from the TMN and dorsal striatum of freely
moving rats. Histamine was measured in 15-min fractions and expressed as a percentage of spontaneous release, calculated as described in Fig. 2. (A) Arachidonyl-
2¢chloroethylamide ⁄N-(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA) was infused into the TMN and histamine release was measured from the TMN
(lower panel) and the dorsal striatum (upper panel). (B) R(+)-Methanandamide (mAEA) was infused in the TMN and histamine release was measured in the TMN
(lower panel) and dorsal striatum (upper panel). Bars indicate the period of drug application. Shown are means ± SEM of four–five experiments. **P < 0.01;
*P < 0.05 vs. last sample before drug treatment (anova and Fisher’s test).
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additional 60 min. Co-application of AM251 with mAEA in the TMN
completely abolished the stimulatory effect of mAEA on histamine
release, both in the TMN and NBM (Fig. 6A and B; n ¼ 6).
Perfusion of TMN with the CB1-r antagonist blocked the effect of
AM404 on histamine release
As shown in Fig. 6C, after collection of four 15-min baseline samples,
200 nm AM251 was added to the perfusing medium for 15 min, and
then it was administered in combination with 100 lm AM404 for an
additional 60 min. AM251 completely blocked the effect of AM404
on histamine release in the TMN (n ¼ 3).
CB1-r immunostaining in the posterior hypothalamus
We examined if CB1-r are localized on histaminergic neurons in the
hypothalamus by performing double immunofluorescence labelling of
Fig. 5. Endocannabinoids modulate histamine release in the tuberomamillary nuclei (TMN) of freely moving rats. Histamine was measured in 15-min fractions and
expressed as a percentage of spontaneous release, calculated as described in Fig. 2. (A) AM404 was infused into the TMN and histamine release was measured from
the TMN (lower panel) and nucleus basalis magnocellularis (NBM; upper panel). (B) AM251 was infused into the TMN and histamine release was measured from
the TMN and (lower panel) and NBM (upper panel). Bars indicate the period of drug application. Shown are means ± SEM of five experiments (A and B).
**P < 0.01; *P < 0.05 vs. last sample before drug treatment (anova and Fisher’s test).
Fig. 6. Cannabinoid-induced increase of histamine release involves activation of CB1-r in the tuberomamillary nuclei (TMN) of freely moving rats. Histamine was
measured in 15-min fractions and expressed as a percentage of spontaneous release, calculated as described in Fig. 2. (A and B) The selective CB1-r antagonist
AM251 was infused into the TMN 15 min before adding R(+)-methanandamide (mAEA) and maintained in the perfusing medium during administration of the
agonist. (C) AM251 was infused in the TMN 15 min before adding AM404 and maintained during administration of the endocannabinoid uptake inhibitor. Bars
indicate the period of drug application. Each point represents the means ± SEM of six (A and B) and three experiments (C).
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hypothalamic slices using a combination of anti-CB1-r antibodies and
anti-HDC antibodies to identify histaminergic neurons. The distribu-
tion profile of HDC-immunoreactive neurons in the E2–E3 subdivi-
sions of the TMN is shown in Fig. 7A and B. CB1-r immunostaining
was sparse in this region, indicating the presence of very few CB1-r-
expressing fibres. A higher density of CB1-r immunostaining was
found in the E4–E5 subdivisions of the TMN (Fig. 7C and D), where
CB1-r immunostaining apparently surrounds clusters of HDC-immu-
nonegative cells. Analysis of optical scan volumes showed that CB1-r
immunostaining did not co-localize to HDC positive cell bodies
(Fig. 7, insets), nor dendrites (not shown). Despite the very low CB1-r
immunostaining in the hypothalamus, CA3 hippocampal neurons were
densely immunolabelled (Fig. 7E), as previously reported by Tsou
et al. (1998). Analysis of optical scan volumes in this region as well
failed to show co-localization of CB1-r and HDC immunostaining (not
shown). The specificity of CB1-r immunostaining in the hypothalamus
was further confirmed preabsorbing the anti-CB1-r antibodies with
glutathione-S-transferase-conjugated fusion protein (Fig. 7F).
Perfusion of the TMN with mAEA did not modify spontaneous
release of GABA from the hypothalamus
We investigated whether the increased histamine release elicited by
CB1-r agonists involved modulation of intrahypothalamic GABA
release. GABA content measured in dialysates collected from the
TMN perfused with 1 lm mAEA for 60 min did not significantly
change (spontaneous release, 0.80 ± 0.14 pmol ⁄ 15 min; n ¼ 7; data
not shown). As such, it is unlikely that the excitatory effect of CB1-r
agonists on histaminergic neurons is mediated by the reduction of an
inhibitory GABAergic tone. However, the activity of histaminergic
cells is controlled by a tonic release of GABA, as perfusion of the
TMN with the GABAA receptor antagonist bicuculline (10 lm) for
75 min significantly increased histamine spontaneous release from the
TMN up to 91 ± 16% (Fig. 8A, lower panel) but, surprisingly, not
from the NBM (Fig. 8A, upper panel; n ¼ 4). Co-administration in the
TMN of bicuculline and ACEA (150 nm) increased significantly
histamine release from the NBM (196 ± 87.7% of baseline; Fig. 8B,
upper panel), and induced an additional increase of TMN histamine
release over that induced by 10 lm bicuculline alone (Fig. 8B, lower
panel; n ¼ 5). We compared the percentage of histamine release
calculated by averaging histamine content in all samples collected
during pharmacological stimulations, and found that ACEA increased
histamine release from the TMN by 82 ± 14%, bicuculline by
65 ± 9% and both compounds together by 136 ± 21% (Fig. 8C),
therefore bicuculline did not occlude the effect of ACEA on histamine
release. The administration of bicuculline likely induces strong local
depolarization, which, in turn, might induce release of endocannabi-
noids. We tested this hypothesis co-administering AM251, at the
concentration (200 nm) that fully blocked the effect of mAEA,
together with bicuculline (10 lm). After collection of four 15-min
baseline samples, AM251 was added to the perfusing medium for
15 min, and then it was administered in combination with bicuculline
(Fig. 8D). A significant increase (85 ± 17%) was achieved during the
second, 15-min period of TMN perfusion with AM251 and bicuculline
and returned to basal levels during wash out in the presence of AM251
(n ¼ 6).
Discussion
In summary, cannabinoids activate the histaminergic system in the rat
brain in vivo. Acute i.p. administration of the CB1-r agonist ACEA
augmented histamine release from the TMN, where histaminergic
somata are located. This effect was mimicked when the selective CB1-
r agonists ACEA or mAEA were infused locally into the TMN of
freely moving rats via a microdialysis probe, indicating that modu-
lation of histamine release is a local phenomenon mediated within the
hypothalamus. Supposedly, histamine is released by short histaminer-
gic projections within the posterior hypothalamus, as TMN neurons
have extensive axonal arborizations within this brain region (Haas &
Panula, 2003). TMN perfusion with CB1-r agonists increased
histamine release not only from the TMN, but also from two
histaminergic projection areas, the NBM and striatum. Modulation of
histamine release in these regions presumably results from the
activation of ascending histaminergic projections. Furthermore, we
found that exogenous and endogenous cannabinoids differed signifi-
cantly in the regulation of histaminergic cells activity: CB1-r agonists
affected histamine release not only at the site of perfusion, the TMN,
but also in the NBM and striatum, whereas the endocannabinoid
membrane uptake blocker AM404 when administered in the hypo-
thalamus increased histamine release only in the TMN.
Specificity of cannabinoid action
The CB-r ligands used in this study are selective for the CB1-r and the
concentrations used in the microdialysis experiments were consistent
with the range of concentrations considered selective for this receptor.
In our study, cannabimimetic compounds were used at similar or lower
concentrations than those effective to modulate synaptic activity
in vitro (e.g. Melis et al., 2004; Marcaggi & Attwell, 2005). The CB1-
r antagonist AM251 effectively blocked both mAEA- and AM404-
induced increase of histamine release at a concentration (200 nm) well
below the range that decreases glutamate release from striatal
synaptosomes (Ko¨falvi et al., 2003), and that inhibits the depolariza-
tion of synaptoneurosomes induced by the sodium channel, site
2-specific neurotoxin veratridine (Liao et al., 2004). Furthermore, the
observation that AM251 blocked AM404-induced increase of hista-
mine release in the TMN argues against the possibility that AM404
effect may be explained by its affinity for the vanilloid VR1 receptor
(De Petrocellis et al., 2000).
Exogenous vs. endogenous cannabinoid action
The current theory indicates that endocannabinoids are released via
activity-dependent cleavage of membrane lipid precursors and are
immediately released from the cells and metabolized (Di Marzo et al.,
1994; Freund et al., 2003; Piomelli, 2003). Endocannabinoid release
for a single neuron is a relatively rare occurrence, but release
probability may be increased by the convergence of synchronous
synaptic events (Varma et al., 2001; Kim et al., 2002). Indeed,
intrahypothalamic administration of AM251 did not modify histamine
release, suggesting that under resting conditions endocannabinoids
tone is insufficient to modulate the activity of histaminergic neurons.
Furthermore, the lack of an effect on histamine release at both AM251
concentrations tested (200 nm and 10 lm) suggests that CB1-r are not
constitutively active. However, AM404 increased histamine release
from the TMN, strongly suggesting that AM404 inhibited local
endocannabinoid clearance and allowed sufficient accumulation to
activate CB1-r. The increased endocannabinoid tone produced by
AM404 augmented histamine release only in the TMN presumably by
activating a more restricted, or different population of CB1-r than
those activated by the administration of direct-acting CB1-r agonists.
In this regard, it was recently shown that constitutive release of
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endocannabinoids by hypothalamic, proopiomelanocortin neurons
inhibits a GABAergic tone, whereas exogenous CB1-r agonists inhibit
glutamate release as well (Hentges et al., 2005). Alternatively,
endocannabinoids may increase histamine release in a subpopulation
of TMN neurons and, in turn, the released histamine may activate
autoinhibitory H3 receptors on other parts of the TMN. Consistent
with these observations, in vivo studies demonstrated that administra-
tions of AM404 or URB597, an inhibitor of the metabolic pathway of
the endocannabinoid anandamide, do not mimic the full spectrum of
pharmacological responses produced by classical CB1-r agonists
(Gaetani et al., 2003; Solinas et al., 2005). Therefore, understanding in
what circumstances endocannabinoids are released and activate
histaminergic cells warrants further investigations (see below).
CB1-r are not expressed on histaminergic neurons and do not
attenuate GABA release in the hypothalamus
Extensive analysis of the histaminergic neuropil within the hypotha-
lamus and of histaminergic projections to the hippocampus did not
Fig. 8. Comparison of the effects of bicuculline, and of bicuculline in the presence of selective CB1-r ligands. Bicuculline (A) or bicuculline plus arachidonyl-
2¢chloroethylamide ⁄N-(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA) (B) were infused in the tuberomamillary nuclei (TMN), and histamine release
was measured in the TMN (lower panels) and nucleus basalis magnocellularis (NBM; upper panels). Histamine was measured in 15-min fractions and expressed as a
percentage of spontaneous release, calculated as described in Fig. 2. Bars indicate the period of drug application. Each point represents the means ± SEM of six–
seven experiments (anova and Fisher’s test). (C) 15-min changes of histamine release in the presence of ACEA, bicuculline and ACEA + bicuculline. Percentage
histamine release was calculated by averaging histamine content in the samples collected during pharmacological stimulations. **P < 0.01, *P < 0.05 (anova and
Fisher’s test). (D) AM251 (200 nm) was infused in the TMN 15 min before adding bicuculline (10 lm) and maintained in the perfusion medium throughout the
experiment. Histamine was measured in 15-min fractions and expressed as a percentage of spontaneous release, calculated as described in Fig. 2. Bars indicate the
period of drug application. Each point represents the means ± SEM of six experiments. **P < 0.01, *P < 0.05 (anova and Fisher’s test).
Fig. 7. CB1 receptors are not detectable on TMN histaminergic neurons. (A and B) The photomicrographs show HDC-positive cells (green) in the E2–E3
subdivision of the TMN and the sparse immunoreactivity for CB1-r (red). (C and D) In the E4 subdivision, the density of immunoreactive fibres is higher than in E2–
E3, although no co-localization of anti-HDC and anti-CB1-r immunoreactivity was observed. Note the denser CB1-r immunostaining surrounding what appear to be
clusters of HDC-immunonegative cells (arrowhead). Insets show optical scan volumes of the histaminergic cell framed in (D). (E) Anti-CB1-r antibodies densely
stained the neuropil in the CA3 region of the hippocampus. Pyramidal cells are immunonegative but surrounded by immunoreactive fibres. HDC positive projections
are also visible. (F) The photomicrograph shows HDC positive cells in the TMN. Preadsorption of the anti-CB1-r antibodies with glutathione-S-transferase-
conjugated fusion protein resulted in no anti-CB1-r immunostaining. PY, pyramidal cell layer; Scale bars: 120 lm (A and E); 20 lm (B and F); 30 lm (C and D).
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reveal co-expression of CB1-r protein and HDC in the same cells.
Therefore, our data strongly suggest that CB1-r are not localized onto
histaminergic neurons, which makes a direct excitatory effect of CB1-r
activation on histamine release unlikely. CB1-r immunoreactivity in
the hypothalamus was overall very low, as previously reported
(Moldrich & Wenger, 2000), although CB1-r mRNA is expressed in
hypothalamic neurons that release neuropeptides known to modulate
food intake (Cota et al., 2003). This study did not examine if
histaminergic neurons express CB1-r mRNA, therefore this possibility
cannot be completely excluded. A possible explanation for the
excitatory effects of CB1-r agonists on histamine release is therefore
the blockade of an inhibitory action exerted on histaminergic neurons.
Four lines of evidence strongly suggest that the cannabinoids
modulate the activity of histaminergic neurons independently of
GABAergic neurotransmission in the hypothalamus: (1) CB1-r
agonists did not decrease GABA release in the TMN; (2) ACEA,
but not bicuculline, administered in the TMN induced a significant
increase of histamine release in the NBM suggesting different modes
of action; (3) bicuculline did not occlude the increment in histamine
release induced by ACEA in the TMN; (4) the CB1-r antagonist
AM251 did not block the effect of bicuculline on histamine release
from the TMN.
Direct inhibitory actions on TMN neurons have been found also for
galanin and nociceptin (Eriksson et al., 2000). However, preliminary
studies in our laboratory showed that intra-TMN administration of
UFP-101, an antagonist of the nociceptin receptor ORL1, did not
modify histamine release (unpublished observations), indicating that
TMN neurons are not tonically inhibited by nociceptin. Therefore, it is
unlikely that cannabinoids effect on histamine release depend on
depression of nociceptin-mediated hyperpolarization of histaminergic
neurons. The mechanism by which cannabinoids increase histamine
release therefore remains to be elucidated.
Different histaminergic neuronal populations?
It is known that histamine release from the anterior hypothalamus
varies during natural sleep–wakefulness cycles, being lowest during
rapid eye movement sleep (Strecker et al., 2002). In our microdialysis
experiments rats were quiescent or sleeping, and presumably the
activity of histaminergic cells was low. Therefore, we assume that
histaminergic modulation of signal processing in other brain regions,
which depends on behavioural state (Weiler et al., 1998), did not vary
considerably during microdialysis sample collection. Nevertheless,
both ACEA and bicuculline significantly increased histamine release
from the TMN, but had different effects on histamine release from the
NBM. These observations indicate that excitation of histaminergic
neurons might not necessarily produce a broad activation of all
histaminergic projections, and suggests the existence of subpopula-
tions of histaminergic cells that respond differently to pharmacological
manipulations and ⁄ or project to different brain regions. Although
anatomical tracing studies did not reveal any topographical organiza-
tion of the histaminergic projections originating in the TMN (Ko¨hler
et al., 1985; Ericson et al., 1987), histamine-containing neurons were
recently shown to be a functional heterogeneous population, based on
differential activation by acute stress (Miklos & Kovacs, 2003), and on
the expression of different c-subunits that confer different sensitivity
to exogenous GABA (Sergeeva et al., 2002). The observation that
histaminergic neurons are not a homogenous neuronal population may
have relevant consequences in the development of target-specific
drugs that affect only a subset of histaminergic cells, and in reducing
the occurrence of collateral or undesired effects.
Functional implications
Cannabinoids and brain histamine have received much attention
recently, because of the prominent role that they play in regulating
appetite. CB1-r antagonists such as rimonabant reduce food
intake and body weight in animals and humans, and CB1-r
agonists have been approved for the treatment of anorexia (Marx,
2006), whereas antagonists of the H3 receptor are being devel-
oped as anti-obesity (Malmlo¨f et al., 2005). For both the
cannabinoid and histaminergic systems though, the mechanisms
involved in regulating food intake are not clear. Hypothalamic
levels of the endocannabinoid 2-arachydonoylethanolamide increase
during fasting and are lowest during food consumption (Kirkham
et al., 2002); on the other hand, histaminergic cells activity
increases during food presentation to fasted rats (Meynard et al.,
2005) and remains sustained during feeding (Itoh et al., 1991).
However, nothing is known about the temporal and causal
relationship between the histaminergic and cannabinoid systems in
controlling appetitive behaviour, an issue that deserves further
investigation.
Administration of CB1-r agonists in the TMN facilitates histamine
release from the NBM, the major source of cholinergic innervation to
the neocortex. This may explain why systemic, but not local,
administration of CB1-r agonists increases ACh release from the
neocortex (Verrico et al., 2003). Activation of cholinergic neurons
innervating the cortex contributes to arousal mechanism; activation of
histamine H1 receptors in the NBM increases cortical ACh release
(Cecchi et al., 2001) and improves rat performance in the object
recognition test (Orsetti et al., 2002; Malmberg-Aiello et al., 2003). It
may seem counterintuitive that cannabinoids facilitate histamine
release from the NBM, given that cannabinoids have deleterious
effects on cognitive processes (Schneider & Koch, 2002). However,
augmented histamine release is also an indicator of stress (Westerink
et al., 2002), and it is conceivable that protracted occupancy of CB1-r,
as produced following local or systemic administration of CB1-r
agonists, disrupts the spatiotemporal specificity of histamine release in
different brain regions, contributing to maladaptive behavioural
responses.
Administration of CB1-r agonists in the TMN facilitates histamine
release from the striatum as well. The striatum provides the anatomical
substrate for the integration of movements (Brown, 1992), and takes
part in learning and executing adequate behavioural responses to
environmental stimuli (Hyman & Malenka, 2001). Systemic admin-
istration of CB1-r agonists reduces locomotion (McLaughlin et al.,
2005), and histamine induces hypokinetic effects that are accompanied
by altered dopaminergic transmission in the striatum (Chiavegatto
et al., 1998). Therefore, the augmented histamine release in the dorsal
striatum following cannabinoid administration in the TMN may
contribute to direct actions of cannabinoids on striatal neurons
(San˜udo-Pen˜a et al., 1999; Huang et al., 2001; Ko¨falvi et al., 2005),
worsening locomotor activity.
Further research is necessary to determine what role a hyperhist-
aminergic state may play in cannabinoid detrimental effects on
cognitive and locomotor performance, and whether it contributes to
drug-motivated habits that are crucial for the establishment of
addiction.
Acknowledgements
This research was supported by Ministero dell’Universita’ e della Ricerca
Scientifica e tecnologica-FIRB (RBAU017SWS), Fondazione Cassa di Risp-
armio di Firenze Funds and the NIH (DA11322 and DA00286).
1642 G. Cenni et al.
ª The Authors (2006). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 24, 1633–1644
Abbreviations
D9-THC, D9-tetrahydrocannabinol; ACEA, arachidonyl-2¢chloroethylamide ⁄ N-
(2chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide; ACh, acetylcholine; BSA,
bovine serum albumin; CB1-r, cannabinoid receptors 1; GABA, c-aminobu-
tyric acid; HDC, histidine decarboxylase; HPLC, high-performance liquid
chromatography; mAEA, R(+)-methanandamide; NBM, nucleus basalis mag-
nocellularis; NDS, normal donkey serum; OPA, o-phthalaldehyde; PB,
phosphate buffer; TMN, tuberomamillary nuclei.
References
Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L., Pertwee, R.G. &
Makriyannis, A. (1994) (R)-methanandamide: a chiral novel anandamide
possessing higher potency and metabolic stability. J. Med. Chem., 37, 1889–
1893.
Beltramo, M., de Fonseca, F.R., Navarro, M., Calignano, A., Gorriti, M.A.,
Grammatikopoulos, G., Sadile, A.G., Giuffrida, A. & Piomelli, D. (2000)
Reversal of dopamine D(2) receptor responses by an anandamide transport
inhibitor. J. Neurosci., 20, 3401–3407.
Bianchi, L., Della Corte, L. & Tipton, K.F. (1999) Simultaneous determination
of basal and evoked output levels of aspartate, glutamate, taurine and
4-aminobutyric acid during microdialysis and from superfused brain slices.
J. Chromatogr. B, 723, 47–59.
Brown, L. (1992) Somatotopic organization in the rat striatum: evidence for a
combinatorial map. Proc. Natl Acad. Sci. USA, 89, 7403–7407.
Cecchi, M., Passani, M.B., Bacciottini, L., Mannaioni, P.F. & Blandina, P.
(2001) Cortical acetylcholine release elicited by stimulation of
histamine H1 receptors in the nucleus basalis magnocellularis: a dual
probe microdialysis study in the freely moving rat. Eur. J. Neurosci., 13,
68–78.
Chiavegatto, S., Nasello, A.G. & Bernardi, M.M. (1998) Histamine and
spontaneous motor activity: biphasic changes, receptors involved and
participation of the striatal dopamine system. Life Sci., 62, 1875–1888.
Cota, D., Marsicano, G., Tscho¨p, M., Gru¨bler, Y., Flachskamm, C., Schubert,
M., Auer, D., Yassouridis, A., Tho¨ne-Reineke, C., Ortmann, S., Tomassoni,
F., Cervino, C., Nisoli, E., Linthorst, A.C.E., Pasquali, R., Lutz, B., Stalla,
G.K. & Pagotto, U. (2003) The endogenous cannabinoid system affects
energy balance via central orexigenic drive and peripheral lipogenesis.
J. Clin. Invest., 112, 423–431.
De Petrocellis, L., Bisogno, T., Davis, J.B., Pertwee, R.G. & Di Marzo, V.
(2000) Overlap between the ligand recognition properties of the anandamide
transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake
with negligible capsaicin-like activity. FEBS Lett., 483, 52–56.
Deutsch, D.G. & Chin, S.A. (1993) Enzymatic synthesis and degradation of
anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol., 46, 791–
797.
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C.
& Piomelli, D. (1994) Formation and inactivation of endogenous
cannabinoid anandamide in central neurons. Nature, 372, 686–691.
Di Marzo, V. & Matias, I. (2005) Endocannabinoid control of food intake and
energy balance. Nat. Neurosci., 8, 585–589.
Dringenberg, H. & Kuo, M. (2003) Histaminergic facilitation of electrocortico-
graphic activation: role of basal forebrain, thalamus, and neocortex. Eur.
J. Neurosci., 18, 2285–2291.
Ericson, H., Watanabe, T. & Ko¨hler, C. (1987) Morphological analysis of the
tuberomammillary nucleus of the rat brain: delineation of subgroups with
antibody against 1-histidine decarboxylase as a marker. J. Comp. Neurol.,
263, 1–24.
Eriksson, K.S., Stevens, D.R. & Haas, H.L. (2000) Opposite modulation of
histaminergic neurons by nociceptin and morphine. Neuropharmacology, 39,
2492–2498.
Freund, T.F., Katona, I. & Piomelli, D. (2003) Role of endogenous
cannabinoids in synaptic signalling. Physiol. Rev., 83, 1017–1066.
Gaetani, S., Cuomo, V. & Piomelli, D. (2003) Anandamide hydrolysis: a new
target for anti-anxiety drugs? Trends Mol. Med., 9, 474–478.
Gerdeman, G.L., Partridge, J.G., Lupica, C.R. & Lovinger, D.M. (2003) It
could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends
Neurosci., 26, 184–192.
Haas, H. & Panula, P. (2003) The role of histamine and the tuberomamillary
nucleus in the nervous system. Nat. Neurosci. Rev., 4, 121–130.
Ha´jos, N., Katona, I., Naiem, S.S., Mackie, K., Ledent, C., Mody, I. & Freund,
T.F. (2000) Cannabinoids inhibit hippocampal GABAergic transmission and
network oscillations. Eur. J. Neurosci., 12, 3239–3249.
Hentges, S.T., Low, M.J. & Williams, J.T. (2005) Differential regulation of
synaptic inputs by constitutively released endocannabinoids and exogenous
cannabinoids. J. Neurosci., 25, 9746–9751.
Hillard, J., Manna, S., Greenberg, M., Dicamelli, R., Ross, R., Stevenson, L.,
Murphy, V., Pertwee, R. & Campbell, W. (1999) Synthesis and characteriza-
tion of potent and selective agonists of the neuronal cannabinoid receptor
(CB1). J. Pharmacol. Exp. Ther., 289, 1427–1433.
Huang, C.-C., Lo, S.-W. & Hsu, K.-S. (2001) Presynaptic mechanisms
underlying cannabinoid inhibition of excitatory synaptic transmission in rat
striatal neurons. J. Physiol., 532.3, 731–748.
Hyman, S.E. & Malenka, R.C. (2001) Addiction and the brain: the
neurobiology of compulsion and its persistence. Nat. Rev. Neurosci., 2,
695–703.
Itoh, Y., Oishi, R. & Saeki, K. (1991) Feeding-induced increase in the
extracellular concentration of histamine in rat hypothalamus as measured by
in vivo microdialysis. Neurosci. Lett., 125, 235–237.
Jarrahian, A., Manna, S., Edgemond, W.S., Campbell, W.B. & Hillard, C.J.
(2000) Structure–activity relationships among N-arachidonoylethanolamine
(anandamide) head group analogues for the anandamide transporter.
J. Neurochem., 74, 2597–2606.
Kim, J., Isokawa, M., Ledent, C. & Alger, B. (2002) Activation of muscarinic
acetylcholine receptors enhances the release of endogenous cannabinoids in
the hippocampus. J. Neurosci., 22, 10182–10191.
Kirkham, T.C., Williams, C.M., Fezza, F. & Di Marzo, V. (2002)
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation
to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl
glycerol. Br. J. Pharmacol., 136, 550–557.
Knigge, U., Willems, E., Kjaer, A., Jorgensen, H. & Warberg, J. (1999)
Histaminergic and catecholaminergic interactions in the central regulation of
vasopressin and oxytocin secretion. Endocrinology, 140, 3713–3719.
Ko¨falvi, A., Rodrigues, R.J., Ledent, C., Mackie, K., Vizi, E.S., Cunha, R.A. &
Sperla´gh, B. (2005) Involvement of cannabinoid receptors in the regulation
of neurotransmitter release in the rodent striatum: a combined immuno-
chemical and pharmacological analysis. J. Neurosci., 25, 2874–2884.
Ko¨falvi, A., Vizi, E.S., Ledent, C. & Sperla´gh, B. (2003) Cannabinoids
inhibit the release of [3H]glutamate from rodent hippocampal synapto-
somes via a novel CB1 receptor-independent action. Eur. J. Neurosci., 18,
1973–1978.
Ko¨hler, C., Swanson, L., Haglund, L. & Wu, J.Y. (1985) The cytoarchitecture,
histochemistry and projections of the tuberomammillary nucleus in the rat.
Neuroscience, 16, 85–110.
Liao, C., Zheng, J., David, L.S. & Nicholson, R.A. (2004) Inhibition of
voltage-sensitive sodium channels by the cannabinoid 1 receptor antagonist
AM 251 in mammalian brain. Pharmacol. Toxicol., 94, 73–78.
Malmberg-Aiello, P., Ipponi, A., Blandina, P., Bartolini, L. & Schunack, W.
(2003) Pro-cognitive effect of a selective H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine, in the rat object recognition test. Inflam.
Res., 52, S33–S34.
Malmlo¨f, K., Zaragoza, F., Golozoubova, V., Refsgaard, H.H., Cremers, T.,
Raun, K., Wulff, B.S., Johansen, P.B., Westerink, B. & Rimvall, K. (2005)
Influence of a selective histamine H3 receptor antagonist on hypothalamic
neural activity, food intake and body weight. Int. J. Obes., 29, 1402–1412.
Marcaggi, P. & Attwell, D. (2005) Endocannabinoid signaling depends on the
spatial pattern of synapse activation. Nat. Neurosci., 8, 776–781.
Marsicano, G., Wotjak, C.T., Azad, S., Bisogno, T., Rammes, G., Cascio, M.G.,
Hermann, H., Tang, J., Hofmann, C., Zieglgansberger, W., Di Marzo, V. &
Lutz, B. (2002) The endogenous cannabinoid system controls extinction of
aversive memories. Nature, 418, 530–534.
Marx, J. (2006) Drug development. Drugs inspired by a drug. Science, 311,
322–325.
McKinney, M.K. & Cravatt, B.F. (2005) Structure and function of fatty acid
amide hydrolase. Annu. Rev. Biochem., 74, 411–432.
McLaughlin, P.J., Lu, D., Winston, K.M., Thakur, G., Swezey, L.A.,
Makriyannis, A. & Salamone, J.D. (2005) Behavioral effects of the novel
cannabinoid full agonist AM 411. Pharmacol. Biochem. Behav., 81, 78–88.
Melis, M., Pistis, M., Perra, S., Muntoni, A., Pillolla, G. & Gessa, G. (2004)
Endocannabinoids mediate presynaptic inhibition of glutamatergic transmis-
sion in rat ventral tegmental area dopamine neurons through activation of
CB1 receptors. J. Neurosci., 24, 53–62.
Meynard, M.M., Valdes, J.L., Recabarren, M., Seron-Ferre, M. & Torrealba, F.
(2005) Specific activation of histaminergic neurons during daily feeding
anticipatory behavior in rats. Behav. Brain. Res., 158, 311–319.
Miklos, I. & Kovacs, K. (2003) Functional heterogeneity of the responses of
histaminergic neuron subpopulations to various stress challenges. Eur.
J. Neurosci., 18, 3069–3079.
Cannabinoids activate the histaminergic system 1643
ª The Authors (2006). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 24, 1633–1644
Moldrich, G. & Wenger, T. (2000) Localization of the CB1 cannabinoid
receptor in the rat brain. An immunohistochemical study. Peptides, 21,
1735–1742.
Orsetti, M., Ferretti, C., Gamalero, R. & Ghi, P. (2002) Histamine H3-receptor
blockade in the rat nucleus basalis magnocellularis improves place
recognition memory. Psychopharmacology, 159, 133–137.
Paxinos, G. & Watson, C. (1998) The Rat Brain in Stereotaxic Coordinates.
Academic Press, New York.
Pertwee, R.G. (1997) Pharmacology of cannabinoid CBI and CB2 receptors.
Pharmacol. Ther., 74, 129–180.
Piomelli, D. (2003) The molecular logic of endocannabinoid signalling. Nat.
Rev. Neurosci., 4, 873–884.
Pollard, H., Moreau, J., Arrang, J.M. & Schwartz, J.C. (1993) A detailed
autoradiographic mapping of histamine H3 receptors in rat brain areas.
Neuroscience, 52, 169–189.
San˜udo-Pen˜a, M.C., Tsou, K. & Walker, J.M. (1999) Motor actions of
cannabinoids in the basal ganglia output nuclei. Life Sci., 65, 703–713.
Schneider, M. & Koch, M. (2002) The cannabinoid agonist WIN 55,212–2
reduces sensorimotor gating and recognition memory in rats. Behav.
Pharmacol., 13, 29–37.
Sergeeva, O.A., Eriksson, K.S., Sharonova, I.N., Vorobjev, V.S. & Haas, H.L.
(2002) GABA(A) receptor heterogeneity in histaminergic neurons. Eur.
J. Neurosci., 16, 1472–1482.
Sherin, J.E., Elmquist, J.K., Torrealba, F. & Saper, C.B. (1998) Innervation of
tuberomammillary neurons by Gabaergic and galaninergic neurons in the
ventrolateral preoptic nucleus of the rat. J. Neurosci., 18, 4705–4721.
Solinas, M., Panlilio, L.V., Tanda, G., Makriyannis, A., Matthews, S.A. &
Goldberg, S.R. (2005) Cannabinoid agonists but not inhibitors of
endogenous cannabinoid transport or metabolism enhance the reinforcing
efficacy of heroin in rats. Neuropsychopharmacology, 30, 2046–2057.
Strecker, R.E., Nalwalk, J., Dauphin, L.J., Thakkar, M.M., Chen, Y., Ramesh,
V., Hough, L.B. & McCarley, R.W. (2002) Extracellular histamine levels in
the feline preoptic/anterior hypothalmic area during natural sleep-wakeful-
ness and prolonged wakefulness: an in vivo microdialysis study. Neuro-
science., 113, 663–670.
Traiffort, E., Pollard, H., Moreau, J., Ruat, M., Schwartz, J.C., Martinez-Mir,
M.I. & Palacios, J.M. (1992) Pharmacological characterization and
autoradiographic localization of histamine H2 receptors in human brain
identified with [125I]iodoaminopotentidine. J. Neurochem., 59, 290–299.
Tsou, K., Brown, S., San˜udo-Pen˜a, M.C., Mackie, K. & Walker, J.M. (1998)
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat
central nervous system. Neuroscience, 83, 393–411.
Varma, N., Carlson, G.C., Ledent, C. & Alger, B.E. (2001) Metabotropic
glutamate receptors drive the endocannabinoid system in hippocampus.
J. Neurosci., 21, RC188.
Verrico, C.D., Jentsch, J.D., Dazzi, L. & Roth, R.H. (2003) Systemic,
but not local, administration of cannabinoid CB1 receptor agonists
modulate prefrontal cortical acetylcholine efflux in the rat. Synapse, 48,
178–183.
Weiler, H.T., Hasenohrl, R.U., van Landeghem, A.A.L., van Landeghem, M.,
Brankack, J., Huston, J.P. & Haas, H.L. (1998) Differential modulation of
hippocampal signal transfer by tuberomammillary nucleus stimulation in
freely moving rats dependent on behavioral state. Synapse, 28, 294–301.
Westerink, B.H., Cremers, T.I., Vries, J.B.D., Liefers, H., Tran, N. & Boer, P.D.
(2002) Evidence for activation of histamine H3 autoreceptors during
handling stress in the prefrontal cortex of the rat. Synapse, 15, 238–243.
Yamatodani, A., Fukuda, H., Wada, H., Iwaeda, T. & Watanabe, T. (1985)
High-performance liquid chromatographic determination of plasma and brain
histamine without previous purification of biological samples: cation-
exchange chromatography coupled with post-column derivatization fluoro-
metry. J. Chromatogr., 344, 115–123.
Zuardi, A.W., Shirakawa, I., Finkelfarb, E. & Karniol, I.G. (1982) Action of
cannabidiol on the anxiety and other effects produced by delta 9-THC in
normal subjects. Psychopharmacology, 76, 245–250.
1644 G. Cenni et al.
ª The Authors (2006). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 24, 1633–1644
